← All trials
NCT06938347
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 5, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Apr 22, 2025
- Last posted
- Nov 6, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Agitated Solutions, Inc.Lead sponsor
- Northwestern UniversityOfficial
- Bright Research PartnersCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.